Effective plasma concentrations of mycophenolic acid and its glucuronide in systemic lupus erythematosus patients in the remission-maintenance phase
Summary What is known and Objective: Mycophenolate mofetil (MMF) has been reported recently to be effective in the treatment of systemic lupus erythematosus (SLE). The therapeutic range of mycophenolic acid (MPA) in SLE in the remission‐maintenance phase remains to be clarified. The aim of this stu...
Saved in:
| Published in | Journal of clinical pharmacy and therapeutics Vol. 37; no. 2; pp. 217 - 220 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Oxford, UK
Blackwell Publishing Ltd
01.04.2012
Blackwell Hindawi Limited |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Summary
What is known and Objective: Mycophenolate mofetil (MMF) has been reported recently to be effective in the treatment of systemic lupus erythematosus (SLE). The therapeutic range of mycophenolic acid (MPA) in SLE in the remission‐maintenance phase remains to be clarified. The aim of this study was to evaluate the therapeutic efficacy of MMF and predose plasma concentrations of MPA and its phenolic glucuronide (MPAG) in patients with SLE in the remission‐maintenance phase.
Methods: Thirty‐one patients with SLE receiving a fixed dosage regimen of MMF (median and interquartile range, 1500 and 1000–2000 mg/day) for at least 1 month and who had not experienced any adverse drug reactions for more than 3 months were enrolled.
Results: Significant improvement was observed after MMF administration in total haemolytic complement CH50 and its fractions C3 and C4, immunoglobulins IgG, IgA and IgM, anti‐dsDNA antibody, serum concentration of albumin and red blood cell count, even though the mean daily dose of prednisolone was significantly reduced (P = 0·02). Median predose plasma concentrations of MPA and MPAG were 1·95 and 26·2 μg/mL (interquartile ranges, 0·94–2·96 and 18·6–53·7 μg/mL). Predose plasma concentrations of MPA and MPAG correlated significantly with MMF dose (r = 0·64, P < 0·01 and r = 0·39, P = 0·03).
What is new and Conclusions: MMF improved clinical laboratory markers and reduced prednisolone dosage in SLE patients with predose plasma concentration of MPA and MPAG in the interquartile ranges of 0·94–2·96 and 18·6–53·7 μg/mL, respectively. |
|---|---|
| AbstractList | What is known and Objective: Mycophenolate mofetil (MMF) has been reported recently to be effective in the treatment of systemic lupus erythematosus (SLE). The therapeutic range of mycophenolic acid (MPA) in SLE in the remission-maintenance phase remains to be clarified. The aim of this study was to evaluate the therapeutic efficacy of MMF and predose plasma concentrations of MPA and its phenolic glucuronide (MPAG) in patients with SLE in the remission-maintenance phase. Methods: Thirty-one patients with SLE receiving a fixed dosage regimen of MMF (median and interquartile range, 1500 and 1000-2000mg/day) for at least 1month and who had not experienced any adverse drug reactions for more than 3months were enrolled. Results: Significant improvement was observed after MMF administration in total haemolytic complement CH sub(50) and its fractions C3 and C4, immunoglobulins IgG, IgA and IgM, anti-dsDNA antibody, serum concentration of albumin and red blood cell count, even though the mean daily dose of prednisolone was significantly reduced (P=0.02). Median predose plasma concentrations of MPA and MPAG were 1.95 and 26.2 mu g/mL (interquartile ranges, 0.94-2.96 and 18.6-53.7 mu g/mL). Predose plasma concentrations of MPA and MPAG correlated significantly with MMF dose (r=0.64, P<0.01 and r=0.39, P=0.03). What is new and Conclusions: MMF improved clinical laboratory markers and reduced prednisolone dosage in SLE patients with predose plasma concentration of MPA and MPAG in the interquartile ranges of 0.94-2.96 and 18.6-53.7 mu g/mL, respectively. Summary What is known and Objective: Mycophenolate mofetil (MMF) has been reported recently to be effective in the treatment of systemic lupus erythematosus (SLE). The therapeutic range of mycophenolic acid (MPA) in SLE in the remission-maintenance phase remains to be clarified. The aim of this study was to evaluate the therapeutic efficacy of MMF and predose plasma concentrations of MPA and its phenolic glucuronide (MPAG) in patients with SLE in the remission-maintenance phase. Methods: Thirty-one patients with SLE receiving a fixed dosage regimen of MMF (median and interquartile range, 1500 and 1000-2000 mg/day) for at least 1 month and who had not experienced any adverse drug reactions for more than 3 months were enrolled. Results: Significant improvement was observed after MMF administration in total haemolytic complement CH50 and its fractions C3 and C4, immunoglobulins IgG, IgA and IgM, anti-dsDNA antibody, serum concentration of albumin and red blood cell count, even though the mean daily dose of prednisolone was significantly reduced (P = 0·02). Median predose plasma concentrations of MPA and MPAG were 1·95 and 26·2 µg/mL (interquartile ranges, 0·94-2·96 and 18·6-53·7 µg/mL). Predose plasma concentrations of MPA and MPAG correlated significantly with MMF dose (r = 0·64, P < 0·01 and r = 0·39, P = 0·03). What is new and Conclusions: MMF improved clinical laboratory markers and reduced prednisolone dosage in SLE patients with predose plasma concentration of MPA and MPAG in the interquartile ranges of 0·94-2·96 and 18·6-53·7 µg/mL, respectively. WHAT IS KNOWN AND OBJECTIVEMycophenolate mofetil (MMF) has been reported recently to be effective in the treatment of systemic lupus erythematosus (SLE). The therapeutic range of mycophenolic acid (MPA) in SLE in the remission-maintenance phase remains to be clarified. The aim of this study was to evaluate the therapeutic efficacy of MMF and predose plasma concentrations of MPA and its phenolic glucuronide (MPAG) in patients with SLE in the remission-maintenance phase.METHODSThirty-one patients with SLE receiving a fixed dosage regimen of MMF (median and interquartile range, 1500 and 1000-2000mg/day) for at least 1month and who had not experienced any adverse drug reactions for more than 3months were enrolled.RESULTSSignificant improvement was observed after MMF administration in total haemolytic complement CH(50) and its fractions C3 and C4, immunoglobulins IgG, IgA and IgM, anti-dsDNA antibody, serum concentration of albumin and red blood cell count, even though the mean daily dose of prednisolone was significantly reduced (P=0·02). Median predose plasma concentrations of MPA and MPAG were 1·95 and 26·2μg/mL (interquartile ranges, 0·94-2·96 and 18·6-53·7 μg/mL). Predose plasma concentrations of MPA and MPAG correlated significantly with MMF dose (r=0·64, P<0·01 and r=0·39, P=0·03).WHAT IS NEW AND CONCLUSIONSMMF improved clinical laboratory markers and reduced prednisolone dosage in SLE patients with predose plasma concentration of MPA and MPAG in the interquartile ranges of 0·94-2·96 and 18·6-53·7μg/mL, respectively. Mycophenolate mofetil (MMF) has been reported recently to be effective in the treatment of systemic lupus erythematosus (SLE). The therapeutic range of mycophenolic acid (MPA) in SLE in the remission-maintenance phase remains to be clarified. The aim of this study was to evaluate the therapeutic efficacy of MMF and predose plasma concentrations of MPA and its phenolic glucuronide (MPAG) in patients with SLE in the remission-maintenance phase. Thirty-one patients with SLE receiving a fixed dosage regimen of MMF (median and interquartile range, 1500 and 1000-2000mg/day) for at least 1month and who had not experienced any adverse drug reactions for more than 3months were enrolled. Significant improvement was observed after MMF administration in total haemolytic complement CH(50) and its fractions C3 and C4, immunoglobulins IgG, IgA and IgM, anti-dsDNA antibody, serum concentration of albumin and red blood cell count, even though the mean daily dose of prednisolone was significantly reduced (P=0·02). Median predose plasma concentrations of MPA and MPAG were 1·95 and 26·2μg/mL (interquartile ranges, 0·94-2·96 and 18·6-53·7 μg/mL). Predose plasma concentrations of MPA and MPAG correlated significantly with MMF dose (r=0·64, P<0·01 and r=0·39, P=0·03). MMF improved clinical laboratory markers and reduced prednisolone dosage in SLE patients with predose plasma concentration of MPA and MPAG in the interquartile ranges of 0·94-2·96 and 18·6-53·7μg/mL, respectively. Summary What is known and Objective: Mycophenolate mofetil (MMF) has been reported recently to be effective in the treatment of systemic lupus erythematosus (SLE). The therapeutic range of mycophenolic acid (MPA) in SLE in the remission‐maintenance phase remains to be clarified. The aim of this study was to evaluate the therapeutic efficacy of MMF and predose plasma concentrations of MPA and its phenolic glucuronide (MPAG) in patients with SLE in the remission‐maintenance phase. Methods: Thirty‐one patients with SLE receiving a fixed dosage regimen of MMF (median and interquartile range, 1500 and 1000–2000 mg/day) for at least 1 month and who had not experienced any adverse drug reactions for more than 3 months were enrolled. Results: Significant improvement was observed after MMF administration in total haemolytic complement CH50 and its fractions C3 and C4, immunoglobulins IgG, IgA and IgM, anti‐dsDNA antibody, serum concentration of albumin and red blood cell count, even though the mean daily dose of prednisolone was significantly reduced (P = 0·02). Median predose plasma concentrations of MPA and MPAG were 1·95 and 26·2 μg/mL (interquartile ranges, 0·94–2·96 and 18·6–53·7 μg/mL). Predose plasma concentrations of MPA and MPAG correlated significantly with MMF dose (r = 0·64, P < 0·01 and r = 0·39, P = 0·03). What is new and Conclusions: MMF improved clinical laboratory markers and reduced prednisolone dosage in SLE patients with predose plasma concentration of MPA and MPAG in the interquartile ranges of 0·94–2·96 and 18·6–53·7 μg/mL, respectively. |
| Author | Mino, Y. Ogawa, N. Kawakami, J. Shimoyama, K. Naito, T. |
| Author_xml | – sequence: 1 givenname: Y. surname: Mino fullname: Mino, Y. organization: Department of Hospital Pharmacy, Hamamatsu University School of Medicine, Hamamatsu – sequence: 2 givenname: T. surname: Naito fullname: Naito, T. organization: Department of Hospital Pharmacy, Hamamatsu University School of Medicine, Hamamatsu – sequence: 3 givenname: K. surname: Shimoyama fullname: Shimoyama, K. organization: Third Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan – sequence: 4 givenname: N. surname: Ogawa fullname: Ogawa, N. organization: Third Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan – sequence: 5 givenname: J. surname: Kawakami fullname: Kawakami, J. organization: Department of Hospital Pharmacy, Hamamatsu University School of Medicine, Hamamatsu |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25610871$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/21517926$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9ksGO0zAQhi20iO0uvAKyhBBcUmzHsZMLEqqWXVC1cFiExMVynAl1SZxsnED7HjwwE1qKxAFfbM98-see-S_IWegCEEI5W3Jcr7ZLnqosERoDgnG-ZFyoYrl7QBanxBlZMAwmUgt9Ti5i3DLGlBbpI3IueMZ1IdSC_Lyqa3Cj_w60b2xsLXVdcBDGwY6-C5F2NW33rus3ELrGO2qdr6gNFfVjpF-byU1DF3wF1Aca93GEFqFm6qdIYdiPG2jt2EW89SiIunEGMUwHJGPEGklrfRghWKxL-42N8Jg8rG0T4clxvySf3l7drW6S9Yfrd6s368TJIiuSHJSWNaR5JiEFVma5lkxILqyoirzglWBOVZApVSoHlstSp3VWllyqGhTo9JK8OOj2Q3c_QRwNPslB09gA3RQNdkhJkfECyZf_JXmuRS6ZlDmiz_5Bt900BPwHUkplMsfhIPX0SE1lC5XpB9_aYW_-TAaB50fARmebesD2-PiXyxRnqITc6wP3wzewP-U5M7NTzNbMhjCzIczsFPPbKWZn3q8-3s1HFEgOAh6HtzsJ2OGbUTrVmfl8e21W_PaLXusbVPsFQYnEXw |
| CODEN | JCPTED |
| CitedBy_id | crossref_primary_10_1177_0004563216667753 crossref_primary_10_1016_j_semarthrit_2017_01_009 crossref_primary_10_1111_bcp_12462 crossref_primary_10_1002_acr_22993 crossref_primary_10_1016_j_vetimm_2021_110339 crossref_primary_10_1016_j_ejps_2015_06_017 crossref_primary_10_1172_jci_insight_124575 crossref_primary_10_1016_j_ejphar_2022_174826 crossref_primary_10_1007_s40262_013_0124_z crossref_primary_10_1248_yakushi_15_00193 crossref_primary_10_1007_s40262_013_0039_8 |
| ContentType | Journal Article |
| Copyright | 2011 Blackwell Publishing Ltd 2015 INIST-CNRS 2011 Blackwell Publishing Ltd. |
| Copyright_xml | – notice: 2011 Blackwell Publishing Ltd – notice: 2015 INIST-CNRS – notice: 2011 Blackwell Publishing Ltd. |
| DBID | BSCLL IQODW CGR CUY CVF ECM EIF NPM 7T5 7TM 7TO H94 K9. M7N 7X8 |
| DOI | 10.1111/j.1365-2710.2011.01269.x |
| DatabaseName | Istex Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Algology Mycology and Protozoology Abstracts (Microbiology C) MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Oncogenes and Growth Factors Abstracts Algology Mycology and Protozoology Abstracts (Microbiology C) Nucleic Acids Abstracts MEDLINE - Academic |
| DatabaseTitleList | AIDS and Cancer Research Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1365-2710 |
| EndPage | 220 |
| ExternalDocumentID | 4313045471 21517926 25610871 JCPT1269 ark_67375_WNG_C1NZ7L7H_1 |
| Genre | article Clinical Trial Journal Article |
| GroupedDBID | --- .3N .GA .Y3 04C 05W 0R~ 10A 1CY 1OB 1OC 24P 29K 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 6PF 702 7PT 7X7 8-0 8-1 8-3 8-4 8-5 8FI 8FJ 8UM 930 A01 A03 AAESR AAEVG AAHHS AAJEY AAKAS AAONW AASGY AAWTL AAXRX AAZKR ABCQN ABCUV ABDBF ABEML ABIVO ABJNI ABPVW ABUWG ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACFBH ACGFO ACGFS ACIWK ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADEOM ADIZJ ADKYN ADMGS ADOJX ADOZA ADXAS ADZCM ADZMN AEEZP AEGXH AEIMD AENEX AEQDE AEUQT AFBPY AFEBI AFGKR AFKRA AFPWT AFRAH AFZJQ AHEFC AHMBA AIACR AIAGR AIURR AIWBW AJBDE ALAGY ALIPV ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ATUGU AZBYB AZFZN AZVAB BAFTC BDRZF BENPR BFHJK BHBCM BMSDO BMXJE BROTX BRXPI BSCLL BY8 C45 CAG CCPQU COF CS3 D-6 D-7 D-E D-F D-I DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EAD EAP EAS EBB EBC EBD EBS EBX ECF ECT ECV EIHBH EJD EMB EMK EMOBN ENC ENX EPT ESX EX3 F00 F5P FEDTE FUBAC FYUFA FZ0 G-S G.N GODZA GWYGA H.X HF~ HMCUK HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LSO LUTES LW6 LYRES MK0 MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PIMPY PQQKQ Q.N Q11 QB0 Q~Q R.K RHX RIWAO RJQFR ROL RX1 SAMSI SUPJJ SV3 TEORI TUS UB1 UKHRP V8K W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WOHZO WOW WQ9 WQJ WUP WVDHM WXI WXSBR XG1 YCJ YFH YOC YUY ZGI ZZTAW ~IA ~WT AAJUZ AAVGM ABCVL ABHUG ABPTK ABWRO ACXME ADAWD ADDAD AFVGU AGJLS AJAOE AKALU IQODW CGR CUY CVF ECM EIF NPM 7T5 7TM 7TO H94 K9. M7N 7X8 |
| ID | FETCH-LOGICAL-c4959-8e674fe3854e3e0b587402412a2d9891d20c6de566b6cea14b73f5bb146fe6e73 |
| IEDL.DBID | DR2 |
| ISSN | 0269-4727 |
| IngestDate | Fri Aug 16 23:10:11 EDT 2024 Fri Aug 16 20:59:46 EDT 2024 Thu Oct 10 16:51:38 EDT 2024 Sat Sep 28 08:00:20 EDT 2024 Sun Oct 22 16:07:55 EDT 2023 Sat Aug 24 01:01:55 EDT 2024 Wed Oct 30 09:57:56 EDT 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | Antineoplastic agent Skin disease Mycophenolic acid Phenolic acid Autoimmune disease Glucuroconjugate Systemic lupus erythematosus Systemic disease Remission prednisolone dose reduction Dose Prednisolone Human Corticosteroid Immunopathology Connective tissue disease Treatment efficiency Antiinflammatory agent Immunomodulator Treatment Adrenal hormone therapeutic efficacy Immunosuppressive agent Inosine monophosphate dehydrogenase inhibitor Pharmacokinetics mycophenolic acid phenolic glucuronide |
| Language | English |
| License | CC BY 4.0 2011 Blackwell Publishing Ltd. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4959-8e674fe3854e3e0b587402412a2d9891d20c6de566b6cea14b73f5bb146fe6e73 |
| Notes | ark:/67375/WNG-C1NZ7L7H-1 istex:C84DE5430238B05975624BE79D2FFEFCB0F24E0A ArticleID:JCPT1269 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
| OpenAccessLink | https://doi.org/10.1111/j.1365-2710.2011.01269.x |
| PMID | 21517926 |
| PQID | 1866548710 |
| PQPubID | 37505 |
| PageCount | 4 |
| ParticipantIDs | proquest_miscellaneous_926642519 proquest_miscellaneous_1872840448 proquest_journals_1866548710 pubmed_primary_21517926 pascalfrancis_primary_25610871 wiley_primary_10_1111_j_1365_2710_2011_01269_x_JCPT1269 istex_primary_ark_67375_WNG_C1NZ7L7H_1 |
| PublicationCentury | 2000 |
| PublicationDate | April 2012 |
| PublicationDateYYYYMMDD | 2012-04-01 |
| PublicationDate_xml | – month: 04 year: 2012 text: April 2012 |
| PublicationDecade | 2010 |
| PublicationPlace | Oxford, UK |
| PublicationPlace_xml | – name: Oxford, UK – name: Oxford – name: England |
| PublicationTitle | Journal of clinical pharmacy and therapeutics |
| PublicationTitleAlternate | J Clin Pharm Ther |
| PublicationYear | 2012 |
| Publisher | Blackwell Publishing Ltd Blackwell Hindawi Limited |
| Publisher_xml | – name: Blackwell Publishing Ltd – name: Blackwell – name: Hindawi Limited |
| References | Sintchak MD, Fleming MA, Futer O et al. Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid. Cell, 1996;85:921-930. Contreras G, Pardo V, Leclercq B et al. Sequential therapies for proliferative lupus nephritis. The New England Journal of Medicine, 2004;350:971-980. Neumann I, Fuhrmann H, Fang IF, Jaeger A, Bayer P, Kovarik J Association between mycophenolic acid 12-h trough levels and clinical endpoints in patients with autoimmune disease on mycophenolate mofetil. Nephrology Dialysis Transplantation, 2008;23:3514-3520. Prémaud A, Rousseau A, Picard N, Marquet P Determination of mycophenolic acid plasma levels in renal transplant recipients co-administered sirolimus: comparison of an enzyme multiplied immunoassay technique (EMIT) and liquid chromatography-tandem mass spectrometry. Therapeutic Drug Monitoring, 2006;28:274-277. Karim MY, Alba P, Cuadrado MJ et al. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology (Oxford), 2002;41:876-882. Mino Y, Naito T, Matsushita T, Kagawa Y, Kawakami J Simultaneous determination of mycophenolic acid and its glucuronides in human plasma using isocratic ion pair high-performance liquid chromatography. Journal of Pharmaceutical and Biomedical Analysis, 2008;46:603-608. Kiberd BA, Lawen J, Fraser AD, Keough-Ryan T, Belitsky P Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation. American Journal of Transplantation, 2004;4:1079-1083. Weber LT, Shipkova M, Armstrong VW et al. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German study group on mycophenolate mofetil therapy. Journal of the American Society of Nephrology, 2002;13:759-768. Neumann I, Haidinger M, Jäger H et al. Pharmacokinetics of mycophenolate mofetil in patients with autoimmune diseases compared renal transplant recipients. Journal of the American Society of Nephrology, 2003;14:721-727. Ginzler EM, Dooley MA, Aranow C et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. The New England Journal of Medicine, 2005;353:2219-2228. Chatham WW, Kimberly RP Treatment of lupus with corticosteroids. Lupus, 2001;10:140-147. Bullingham RE, Nicholls AJ, Kamm BR Clinical pharmacokinetics of mycophenolate mofetil. Clinical Pharmacokinetics, 1998;34:429-455. Nowak I, Shaw LM Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clinical Chemistry, 1995;41:1011-1017. Jiang YZ, Ji XH, Ji YF, Su DL The abnormal expression of IL-10, IFN-γ, IP-10 and IL-12 in patients with systemic lupus erythematosus and the effects of cyclosporine A and cyclophosphamide on it. Acta Universitatis Medicinalis Nanjing, 2005;25:633-636. Mino Y, Naito T, Otsuka A et al. Cyclosporine concentration-dependent increase in concentration ratio of mycophenolic acid acyl and phenol glucuronides to mycophenolic acid in stable kidney transplant recipients. Clinical Biochemistry, 2009;42:595-601. Mino Y, Naito T, Matsushita T et al. Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation. Therapeutic Drug Monitoring, 2008;30:656-661. Schütz E, Shipkova M, Armstrong VW et al. Therapeutic drug monitoring of mycophenolic acid: comparison of HPLC and immunoassay reveals new MPA metabolites. Transplantation Proceedings, 1998;30:1185-1187. Kingdon EJ, McLean AG, Psimenou E et al. The safety and efficacy of MMF in lupus nephritis: a pilot study. Lupus, 2001;10:606-611. Su DL, Wang HJ, Ji XH et al. Mycophenolic acid inhibits SLE-associated cytokine expression and promotes apoptosis of peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Acta Pharmacologica Sinica, 2006;27:1051-1057. Buratti S, Szer IS, Spencer CH, Bartosh S, Reiff A Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. The Journal of Rheumatology, 2001;28:2103-2108. Zahr N, Amoura Z, Debord J et al. Pharmacokinetic study of mycophenolate mofetil in patients with systemic lupus erythematosus and design of Bayesian estimator using limited sampling strategies. Clinical Pharmacokinetics, 2008;47:277-284. Atcheson BA, Taylor PJ, Kirkpatrick CM et al. Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia. Therapeutic Drug Monitoring, 2004;26:284-286. van Gelder T, Le Meur Y, Shaw LM et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Therapeutic Drug Monitoring, 2006;28:145-154. Joy MS, Hilliard T, Hu Y et al. Pharmacokinetics of mycophenolic acid in patients with lupus nephritis. Pharmacotherapy, 2009;29:7-16. Mourad M, Malaise J, Chaib Eddour D et al. Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. Clinical Chemistry, 2001;47:1241-1248. Filler G, Hansen M, LeBlanc C et al. Pharmacokinetics of mycophenolate mofetil for autoimmune disease in children. Pediatric Nephrology, 2003;18:445-449. Czock D, Rasche FM, Carius A et al. Pharmacokinetics and pharmacodynamics of mycophenolic acid after enteric-coated mycophenolate versus mycophenolate mofetil in patients with progressive IgA nephritis. The Journal of Clinical Pharmacology, 2007;47:850-859. Appel GB, Contreras G, Dooley MA et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. Journal of the American Society of Nephrology, 2009;20:1103-1112. Wang J, Hu W, Xie H et al. Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide. Lupus, 2007;16:707-712. Vethe NT, Bremer S, Rootwelt H, Bergan S Pharmacodynamics of mycophenolic acid in CD4+ cells: a single-dose study of IMPDH and purine nucleotide responses in healthy individuals. Therapeutic Drug Monitoring, 2008;30:647-655. Neumann I, Fuhrmann H, Kanzler M et al. Pharmacokinetics of enteric-coated mycophenolate sodium: comparative study in patients with autoimmune disease and renal allograft. Expert Opinion on Pharmacotherapy, 2008;9:879-886. 2009; 20 2009; 42 2005; 353 2002; 13 2004; 26 2004; 4 2008; 9 2003; 14 2003; 18 2001; 28 2008; 30 2001; 47 2009; 29 2007; 16 2005; 25 1995; 41 2002; 41 2004; 350 2006; 27 2006; 28 2008; 47 2008; 23 1996; 85 2008; 46 1998; 30 1998; 34 2007; 47 2001; 10 |
| References_xml | – volume: 34 start-page: 429 year: 1998 end-page: 455 article-title: Clinical pharmacokinetics of mycophenolate mofetil publication-title: Clinical Pharmacokinetics – volume: 353 start-page: 2219 year: 2005 end-page: 2228 article-title: Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis publication-title: The New England Journal of Medicine – volume: 47 start-page: 277 year: 2008 end-page: 284 article-title: Pharmacokinetic study of mycophenolate mofetil in patients with systemic lupus erythematosus and design of Bayesian estimator using limited sampling strategies publication-title: Clinical Pharmacokinetics – volume: 18 start-page: 445 year: 2003 end-page: 449 article-title: Pharmacokinetics of mycophenolate mofetil for autoimmune disease in children publication-title: Pediatric Nephrology – volume: 25 start-page: 633 year: 2005 end-page: 636 article-title: The abnormal expression of IL‐10, IFN‐γ, IP‐10 and IL‐12 in patients with systemic lupus erythematosus and the effects of cyclosporine A and cyclophosphamide on it publication-title: Acta Universitatis Medicinalis Nanjing – volume: 46 start-page: 603 year: 2008 end-page: 608 article-title: Simultaneous determination of mycophenolic acid and its glucuronides in human plasma using isocratic ion pair high‐performance liquid chromatography publication-title: Journal of Pharmaceutical and Biomedical Analysis – volume: 26 start-page: 284 year: 2004 end-page: 286 article-title: Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia publication-title: Therapeutic Drug Monitoring – volume: 28 start-page: 274 year: 2006 end-page: 277 article-title: Determination of mycophenolic acid plasma levels in renal transplant recipients co‐administered sirolimus: comparison of an enzyme multiplied immunoassay technique (EMIT) and liquid chromatography‐tandem mass spectrometry publication-title: Therapeutic Drug Monitoring – volume: 29 start-page: 7 year: 2009 end-page: 16 article-title: Pharmacokinetics of mycophenolic acid in patients with lupus nephritis publication-title: Pharmacotherapy – volume: 30 start-page: 656 year: 2008 end-page: 661 article-title: Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation publication-title: Therapeutic Drug Monitoring – volume: 47 start-page: 850 year: 2007 end-page: 859 article-title: Pharmacokinetics and pharmacodynamics of mycophenolic acid after enteric‐coated mycophenolate versus mycophenolate mofetil in patients with progressive IgA nephritis publication-title: The Journal of Clinical Pharmacology – volume: 30 start-page: 1185 year: 1998 end-page: 1187 article-title: Therapeutic drug monitoring of mycophenolic acid: comparison of HPLC and immunoassay reveals new MPA metabolites publication-title: Transplantation Proceedings – volume: 47 start-page: 1241 year: 2001 end-page: 1248 article-title: Pharmacokinetic basis for the efficient and safe use of low‐dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation publication-title: Clinical Chemistry – volume: 9 start-page: 879 year: 2008 end-page: 886 article-title: Pharmacokinetics of enteric‐coated mycophenolate sodium: comparative study in patients with autoimmune disease and renal allograft publication-title: Expert Opinion on Pharmacotherapy – volume: 10 start-page: 606 year: 2001 end-page: 611 article-title: The safety and efficacy of MMF in lupus nephritis: a pilot study publication-title: Lupus – volume: 350 start-page: 971 year: 2004 end-page: 980 article-title: Sequential therapies for proliferative lupus nephritis publication-title: The New England Journal of Medicine – volume: 85 start-page: 921 year: 1996 end-page: 930 article-title: Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid publication-title: Cell – volume: 20 start-page: 1103 year: 2009 end-page: 1112 article-title: Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis publication-title: Journal of the American Society of Nephrology – volume: 14 start-page: 721 year: 2003 end-page: 727 article-title: Pharmacokinetics of mycophenolate mofetil in patients with autoimmune diseases compared renal transplant recipients publication-title: Journal of the American Society of Nephrology – volume: 4 start-page: 1079 year: 2004 end-page: 1083 article-title: Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation publication-title: American Journal of Transplantation – volume: 41 start-page: 1011 year: 1995 end-page: 1017 article-title: Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics publication-title: Clinical Chemistry – volume: 23 start-page: 3514 year: 2008 end-page: 3520 article-title: Association between mycophenolic acid 12‐h trough levels and clinical endpoints in patients with autoimmune disease on mycophenolate mofetil publication-title: Nephrology Dialysis Transplantation – volume: 10 start-page: 140 year: 2001 end-page: 147 article-title: Treatment of lupus with corticosteroids publication-title: Lupus – volume: 13 start-page: 759 year: 2002 end-page: 768 article-title: The pharmacokinetic‐pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German study group on mycophenolate mofetil therapy publication-title: Journal of the American Society of Nephrology – volume: 16 start-page: 707 year: 2007 end-page: 712 article-title: Induction therapies for class IV lupus nephritis with non‐inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide publication-title: Lupus – volume: 27 start-page: 1051 year: 2006 end-page: 1057 article-title: Mycophenolic acid inhibits SLE‐associated cytokine expression and promotes apoptosis of peripheral blood mononuclear cells from patients with systemic lupus erythematosus publication-title: Acta Pharmacologica Sinica – volume: 42 start-page: 595 year: 2009 end-page: 601 article-title: Cyclosporine concentration‐dependent increase in concentration ratio of mycophenolic acid acyl and phenol glucuronides to mycophenolic acid in stable kidney transplant recipients publication-title: Clinical Biochemistry – volume: 41 start-page: 876 year: 2002 end-page: 882 article-title: Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents publication-title: Rheumatology (Oxford) – volume: 28 start-page: 145 year: 2006 end-page: 154 article-title: Therapeutic drug monitoring of mycophenolate mofetil in transplantation publication-title: Therapeutic Drug Monitoring – volume: 30 start-page: 647 year: 2008 end-page: 655 article-title: Pharmacodynamics of mycophenolic acid in CD4+ cells: a single‐dose study of IMPDH and purine nucleotide responses in healthy individuals publication-title: Therapeutic Drug Monitoring – volume: 28 start-page: 2103 year: 2001 end-page: 2108 article-title: Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus publication-title: The Journal of Rheumatology |
| SSID | ssj0006723 |
| Score | 2.0476553 |
| Snippet | Summary
What is known and Objective: Mycophenolate mofetil (MMF) has been reported recently to be effective in the treatment of systemic lupus erythematosus... Mycophenolate mofetil (MMF) has been reported recently to be effective in the treatment of systemic lupus erythematosus (SLE). The therapeutic range of... Summary What is known and Objective: Mycophenolate mofetil (MMF) has been reported recently to be effective in the treatment of systemic lupus erythematosus... What is known and Objective: Mycophenolate mofetil (MMF) has been reported recently to be effective in the treatment of systemic lupus erythematosus (SLE). The... WHAT IS KNOWN AND OBJECTIVEMycophenolate mofetil (MMF) has been reported recently to be effective in the treatment of systemic lupus erythematosus (SLE). The... |
| SourceID | proquest pubmed pascalfrancis wiley istex |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 217 |
| SubjectTerms | Adult Biological and medical sciences Dose-Response Relationship, Drug Female Glucocorticoids - administration & dosage Glucocorticoids - therapeutic use Glucuronides - pharmacokinetics Humans Immunosuppressive Agents - administration & dosage Immunosuppressive Agents - pharmacokinetics Immunosuppressive Agents - therapeutic use Lupus Erythematosus, Systemic - drug therapy Lupus Erythematosus, Systemic - physiopathology Male Medical sciences Middle Aged mycophenolic acid Mycophenolic Acid - administration & dosage Mycophenolic Acid - analogs & derivatives Mycophenolic Acid - pharmacokinetics Mycophenolic Acid - therapeutic use mycophenolic acid phenolic glucuronide pharmacokinetics Pharmacology. Drug treatments Prednisolone - administration & dosage Prednisolone - therapeutic use prednisolone dose reduction Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis systemic lupus erythematosus therapeutic efficacy Treatment Outcome |
| Title | Effective plasma concentrations of mycophenolic acid and its glucuronide in systemic lupus erythematosus patients in the remission-maintenance phase |
| URI | https://api.istex.fr/ark:/67375/WNG-C1NZ7L7H-1/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1365-2710.2011.01269.x https://www.ncbi.nlm.nih.gov/pubmed/21517926 https://www.proquest.com/docview/1866548710 https://search.proquest.com/docview/1872840448 https://search.proquest.com/docview/926642519 |
| Volume | 37 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELbQnrjwfgSWlZFQT5sqT7s5osJSrWBVoa5YcbHseCKqbtOqaaQtJ34CJ34gv4QZO9tStFwQtzycl_XZ840z8w1jrwyZXRtVIZRVGmZWmlBHIEIto6QQAzuIDK13fDgTo_Ps9CK_6OKfKBfG60NsF9xoZLj5mga4Ns3-IPf5VBTN7JQ440QUfeKTcSopuuvNx52SlJCu0ht6HEWYoc3eD-q58UZIV6mnryhcUjfYY5UvdXETF92nts42ndxls-uv8iEps367Nv3y6x-Cj__ns--xOx2F5a895u6zW1A_YL2x18DeHPPJLqWrOeY9Pt6pY28esh9eLxknWb5E5j7XvKTMybqT7234ouLzTUlyBzVpFnNdTi3XteXTdcMpwr4lOV8LfFpzr0ONjS7bZdtwWG28CO2iwb1OMrahhniYr6i0HS0O_vz2fa5JJ4PERvA1vqAlf8TOT95OhqOwKw4RlplbugQhswrSQZ5BCpHJqbYg0pFEJ7YYFLFNolJYQLZqRAk6zoxMq9wYtAwVCJDpY3ZQL2p4yrisEon4yFOtLdl0A3EBSGMKU4HOhA5YzwFBLb0AiNKrGcXDyVx9OnunhvHZZ_lejlQcsKM9pGwvSIilomsasMNr6KhurmiUkxxEvzGOAvZyexp7hH7d6BoWLbWRyCMi9KUDxv_SpkCulVEicsCeeFTunh-TElsiAiYdtrYnfnMBEVWKUKUIVcqhSl2p0-F4QpvP_vnK5-w2Hk98tNMhO1ivWniBRG5tjtwQ_QXarT9- |
| link.rule.ids | 315,783,787,1378,27936,27937,46306,46730 |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9NAEB2hcoAL31BDKYuEcqorf-7GRxQooaRRhFJRcVntetciauNEcSw1nPgJnPiB_BJmvG5CULkgbnG8tuPVm503k9k3AK80uV0TFL7Ni9hPjNC-Ciz3lQiijHdNN9CU7zgZ8v5pcnyWnrXtgGgvjNOHWCfcyDKa9ZoMnBLS21buNlRROXMjxRlGPDtEQnkTrT-mPg5vPm60pLhoer1hzJH5CXrt7bKea--EhJXm-pIKJlWFc1a4ZhfXsdFtctt4p6O7cHH1Xq4o5fywXurD_Osfko__6cXvwZ2WxbLXDnb34YYtH0Bn5GSwVwdsvNnVVR2wDhttBLJXD-GHk0zGdZbNkbxPFctp82TZKvhWbFaw6SonxYOSZIuZyieGqdKwybJiVGRfk6KvsWxSMidFjYMu6nldMbtYOR3aWYVHrWpsRQPxa7ag7naUH_z57ftUkVQG6Y3gz_iCzvwRnB69Hff6ftsfws-TJntpuUgKG3fTxMY20Cm1F0RGEqnIZN0sNFGQc2ORsGqeWxUmWsRFqjU6h8JyK-LHsFPOSrsLTBSRQICksVKG3Lq2YWaRyWS6sCrhyoNOgwQ5dxogUi3OqSROpPLT8J3shcPPYiD6MvRgfwsq6wsiIqoYnXqwd4Ud2S4XlWxUBzF0DAMPXq5P44zQvzeqtLOaxgikEgGG0x6wv4zJkG4ltBfZgycOlpvnhyTGFnEPRAOu9YnfokBElSRUSUKVbFAlL-VxbzSmj0__-coXcKs_PhnIwfvhh2dwG8dErvhpD3aWi9o-R1631PuNvf4CpfFDlg |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nj9MwELXQIiEufMMGlsVIqKfNKp92c0SFUpalqlBXrLhYdmyLqjStmkbacuIncOIH8kuYsbMtRcsFcWuaSdJYz5437swbQl4odLs6sqEpbRpmmqtQRoaFkkdJwbq6Gync73g_ZIOz7OQ8P2_zn7AWxutDbDbccGa49Ron-ELb3Unu66kwm9kpccYJK46BT17PGBBhJEgftlJSjLtWbxByFGEGTns3q-fKOwFfxaG-wHxJWcOQWd_r4ioyusttnXPq3ybTy9fyOSnT42aljsuvfyg-_p_3vkNutRyWvvSgu0uumeoe6Yy8CPb6iI63NV31Ee3Q0VYee32f_PCCybDK0gVQ95mkJZZOVq1-b03nls7WJeodVChaTGU50VRWmk5WNcUU-wb1fLWhk4p6IWow-tIsmpqa5dqr0M5rOGo1Y2s0hK_pEnvb4e7gz2_fZxKFMlBtBH7GZ3DlD8hZ__W4Nwjb7hBhmbm9S8N4Zk3azTOTmkjl2FwQ-EgiE110i1gnUcm0AbqqWGlknCme2lwpcA3WMMPTh2Svmldmn1BuEw74yFMpNTp1ZeLCAI8plDUyYzIgHQcEsfAKIEIup5gQx3PxcfhG9OLhJ37KByIOyOEOUjYXJEhTITYNyMEldES7WNTCaQ5C4BhHAXm-OQ0jgv_dyMrMG7ThQCQiCKYDQv9iUwDZyrASOSCPPCq3z49Rii1hAeEOW5sTv8WAgCqBqBKIKuFQJS7ESW80xo-P__nKZ-TG6FVfnL4dvntCboJJ4jOfDsjeatmYp0DqVurQzdZfo9VCRQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effective+plasma+concentrations+of+mycophenolic+acid+and+its+glucuronide+in+systemic+lupus+erythematosus+patients+in+the+remission-maintenance+phase&rft.jtitle=Journal+of+clinical+pharmacy+and+therapeutics&rft.au=Mino%2C+Y.&rft.au=Naito%2C+T.&rft.au=Shimoyama%2C+K.&rft.au=Ogawa%2C+N.&rft.date=2012-04-01&rft.pub=Blackwell+Publishing+Ltd&rft.issn=0269-4727&rft.eissn=1365-2710&rft.volume=37&rft.issue=2&rft.spage=217&rft.epage=220&rft_id=info:doi/10.1111%2Fj.1365-2710.2011.01269.x&rft.externalDBID=n%2Fa&rft.externalDocID=ark_67375_WNG_C1NZ7L7H_1 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0269-4727&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0269-4727&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0269-4727&client=summon |